世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のワクチン市場の展望、2028年


Global Vaccines Market Outlook, 2028

ワクチンは、世界中の何十億もの人々を守るための、最も強力で費用対効果の高い方法である。ワクチン開発は、豊かな国の人々の生命を脅かす感染症の負担をなくし、健康を一変させる可能性を秘めている。世界保健... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Bonafide Research & Marketing Pvt. Ltd.
ボナファイドリサーチ 		2023年9月30日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		194 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

ワクチンは、世界中の何十億もの人々を守るための、最も強力で費用対効果の高い方法である。ワクチン開発は、豊かな国の人々の生命を脅かす感染症の負担をなくし、健康を一変させる可能性を秘めている。世界保健機関（WHO）は、予防接種に対する認識と政府の取り組みが、年間200万〜300万人の死亡を防ぐのに役立っていると述べている。企業の合併や提携と相まって、投資の拡大が製品の生産と販売を世界的に後押ししている。ワクチン市場の展望によると、世界的な疾病の発生率の上昇がワクチンの採用を促し、ワクチン市場の成長の見通しを生み出している。結核、癌、インフルエンザ、肺炎といった致死率の高い疾病は、人々に予防接種を選択させる要因となっている。例えば、世界保健機関（WHO）によると、2020年には約150万人が結核で死亡し、1,000万人以上が結核で倒れた。さらに、ワクチン接種の利点に関する一般市民の意識の高まりや、研究開発における政府支援の増加は、ワクチン市場の成長の触媒として作用する可能性が高い。慢性疾患や感染症の有病率の上昇、予防接種プログラムの増加、ワクチン技術の進歩、ワクチンに対する考え方の変化などの要因は、予測期間中にワクチン市場の成長を促進すると予想される主な要因の一部である。結核、がん、肝炎、感染症などの致命的な慢性疾患や感染症から子どもたちを守る必要性の高まりは、予測期間中、ワクチンメーカーに有利な機会をもたらすと期待されています。国連児童基金（ユニセフ）によると、毎年ワクチン接種によって300万人以上の子供たちが致命的な病気から救われています。世界中の組織や企業が直面している最大の課題の1つは、マラリア、HIV、結核などの病気に対する効果的な闘いのために試行錯誤を続けていることである。政府と製薬会社は、このような病気に対する製品を開発するための体制を確立するために多大な努力を払っている。さらに、風土病や感染症の流行が増加していることも、予測期間中のワクチン市場の成長を促進すると予想される。

Bonafide Research社の調査レポート「Global Vaccine Market Outlook, 2028」によると、同市場は2022年の682億2,000万米ドルから2028年には1,050億米ドルを超えると予測されている。同市場は、2023-28年までに年平均成長率7.81％で成長すると予測されている。先進的な医療制度に莫大な資本を投資する各国政府は、ワクチン市場規模の拡大を見込んでいる。政府の医療プログラムは、結核やロタウイルスなどの慢性疾患の予防のために乳幼児にワクチンを投与している。H1B1感染症や豚インフルエンザ（H1N1）のような新しい疾病の増加は、疾病の予防に役立つ新しい方法を採用するよう当局を後押ししている。さらに、様々な感染症の発生率の上昇や、病気の早期診断・予防に関する意識の高まりが、予防ワクチンの需要を押し上げ、ワクチン市場の成長を後押ししている。世界的な疾病の発生率の高さによるワクチン需要の増加が、市場成長の原動力となっている。世界保健機関（WHO）は、世界人口の約4%に相当する約3億2,500万人がウイルス性肝炎に罹患していると推定している。加えて、ワクチン技術の進歩は、新たな疾病を標的とする機会を提供し、市場の成長を支えている。生きた病原体の標的減弱技術から、生物学的に設計されたタンパク質やペプチド抗原、ウイルスベクターや核酸ベースの抗原の送達まで、幅広い新しいワクチン接種技術が開発されている。これらの技術のほとんどは、非常に有望な結果をもたらしている。そのため、ワクチン技術開発への支出が大幅に増加しており、これが市場成長を後押ししている。

急速に進化する技術はワクチン市場の動向に大きな影響を与えている。遺伝子工学の導入やラボの自動化といった開発は、ワクチンメーカーが低コストのワクチンを開発するのに役立っている。さらに、新興国政府が大規模なワクチン接種を開始するために行っている様々な取り組みが、将来的にワクチン産業全体の価値を高める可能性がある。ワクチンの開発は、長く複雑で高価なプロセスである。その結果、ほとんどのワクチンは通常高価であり、これがワクチン市場の成長における重要なハードルとなっている。同様に、発展途上地域全体の認識不足や医療インフラの貧弱さも、ワクチン市場へのアクセスを妨げている。ファイザーやGSKのようなワクチン製造大手は、有効性の高い新製品を投入するため、ワクチンの研究開発に積極的に投資している。これに加えて、ワクチンの安全性と有効性を確立するために様々な試験を行っている。例えば、2022年1月、ファイザー社とBioNTech SEは、18歳から55歳の成人を対象に、Omicronベースのワクチン候補の安全性、免疫原性、忍容性を評価する臨床試験を開始した。同市場は、2022年から2028年にかけて大きなCAGRで成長すると予想されている。また、新興疾患への理解が深まるにつれて、過去数年間に数多くのワクチンが開発された。インフルエンザ、DTP、膵臓がんなどに対する効率的なワクチンが入手可能になったことが、市場成長の原動力となっている。さらに、技術の進歩により、鳥インフルエンザワクチン、経鼻インフルエンザワクチン、治療用がんワクチン、卵を使わないワクチンなど、ワクチン開発のマイルストーンが達成されました。ワクチンの開発や疾病の流行とともに、予防接種プログラムや、予防接種率を向上させるための政府当局による支援イニシアティブは、分析期間中、ワクチン産業の展望にプラスの影響を与えるでしょう。

地域別では、北米が2022年の市場シェア35%以上で世界のワクチン市場をリードしている。

北米には、ファイザー、Moderna、ジョンソン・エンド・ジョンソン、メルクなど、世界最大かつ最も影響力のある製薬会社がある。これらの企業は、ワクチンを大規模に開発・製造するための資源、専門知識、研究インフラを有しています。北米企業には、ワクチンの研究開発（R&D）に投資してきた長い歴史があります。このため、COVID-19パンデミックの際に脚光を浴びたmRNAワクチンの開発など、ワクチン革新の最前線に立つことができた。特に米国は、ワクチンの承認と監視に関する規制の枠組みが確立している。米国食品医薬品局（FDA）は、ワクチンの安全性と有効性を確保する上で極めて重要な役割を果たしており、これにより世界的に製品に対する信頼が高まる。北米の製薬会社は、多くの場合、ワクチンの開発・製造を支援する民間資金や公的資金を含む大きな財源を利用することができる。この地域にはワクチン製造のための強固なインフラがあり、大量のワクチンを効率的に製造できる施設が数多くあります。北米はまた、確立された流通網と物流インフラの恩恵を受けており、これらは国内外へのワクチンのタイムリーな供給に不可欠です。北米の製薬会社は、中低所得国におけるワクチンへのアクセスを拡大するため、国際機関や政府、非営利団体と協力することが多い。同地域では、政府や複数の市場参入企業による多額の投資を受け、医療セクターの大幅な成長が見込まれている。さらに、強固な医療インフラと研究センターは、何百万人もの命を救うことに大きく貢献している。米国だけでも、ワクチンは過去20年間に2,100万人以上の入院と73万2,000人の死亡を予防している（CDC）。これとは別に、技術の進歩がこの地域のワクチン市場の成長を後押ししている。最近、2018年10月、米国FDAは、サノフィ・パスツールによるデング熱に対する初の認可ワクチンである「Dengvaxia」の申請を検討することに合意した。米領バージン諸島、プエルトリコ、グアムは、全米でデング熱の有病率が最も高い地域の一部である。

技術面では、予測期間中、結合型ワクチンが世界のワクチン市場でより高い収益を上げ、市場をリードすると予測されている。

世界のワクチン市場は、結合型ワクチン、不活化・サブユニットワクチン、弱毒生ワクチン、組み換えワクチン、トキソイドワクチンなど、様々な技術タイプに区分される。結合型ワクチンは、政府および民間企業による開発費の増加により、ワクチンタイプ別では世界市場でトップシェアを占めています。結合型ワクチンへの嗜好が高まっているのは、抗体の持続性や貪欲性など、様々な付加的特徴があるためである。結合型ワクチンは、特定の細菌などの多糖類カプセルを持つ病原体に対応するように設計されている。多糖カプセルは乳幼児では免疫原性が低いことがあります。結合型ワクチンは、多糖体をキャリアタンパク質に結合させることでこの制限を克服し、免疫原性を高めている。その結果、特に脆弱な集団において、より強力で持続性のある免疫応答が得られる。結合型ワクチンの多くは、インフルエンザ菌b型（Hib）、肺炎球菌（肺炎球菌）、髄膜炎菌（髄膜炎菌）など、重篤で生命を脅かす可能性のある疾患を引き起こす細菌を対象としている。これらのワクチンは、これらの疾患の発生率を大幅に減少させ、公衆衛生の改善につながった。結合型ワクチンは、乳児、幼児、成人など幅広い年齢層に適しています。この汎用性により、包括的なワクチン接種プログラムが可能になり、さまざまな年齢層の個人を保護することができます。混合ワクチンは接種した個人を保護するだけでなく、集団免疫にも貢献します。集団における病原体の有病率を低下させることで、ワクチンを接種していない人でも感染率が低下し、感染リスクを低減することができます。髄膜炎菌と肺炎球菌に対する結合型ワクチンは、重症で死に至る可能性のある2つの感染症である髄膜炎と肺炎の予防に特に成功している。多くの国で、結合型ワクチンを用いた予防接種キャンペーンが成功し、ワクチンで予防可能な疾病の大幅な減少につながっている。こうしたキャンペーンは、特定の細菌感染症のリスクが高い小児や青少年を対象とすることが多い。結合型ワクチンは、その有効性と安全性が証明されているため、世界保健機関（WHO）や各国の保健機関など、主要な保健当局によって推奨されています。

ワクチンの筋肉内および皮下投与経路は、世界のワクチン市場において歴史的な期間を通じて高い市場成長率を示している。

COVID-19ワクチンを除けば、筋肉内および皮下投与が市場の最大シェアを占めている。投与速度、投与量の正確なコントロール、投与の容易さなどの利点により、筋肉内・皮下投与は最も普及している経路の1つとなっており、市場を牽引している。この分野は、他の投与経路と比較して、注射部位での反応率が低い、免疫反応が高いなどの利点があるため、より高い市場成長が予測されている。筋肉内注射は筋肉に、皮下注射は皮膚や脂肪層の下に注射する。筋肉内注射はA型肝炎、B型肝炎、IPV、HPV、PCV-7、Hib、インフルエンザに投与される。しかし、経口投与セグメントは予測期間中に大きなCAGRで成長すると予想されている。経口投与ワクチンの利点である、粘膜免疫と全身免疫の両方の誘発、注射に関連する有害事象の排除などが、市場成長を促進するいくつかの要因である。ポリオワクチン、ロタウイルスワクチン、その他の小児用ワクチンは一般的に経口投与されます。さらに、エンドユーザー別に見ると、ワクチン市場は小児用と成人用に区分される。市場（COVID 19ワクチンを除く）では小児用ユーザーが最大のシェアを占めており、予測期間中は成人用ユーザーが最も高いCAGRを記録すると推定される。小児用ワクチンの市場成長を牽引する要因として、政府のイニシアティブの高まりや、疾病予防のための先進的な小児用ワクチンの開発に対する企業のイニシアティブの高まりなどが予想される。ワクチンの投与には非経口投与が非常に好まれるため、この分野がワクチン市場を支配している。非経口投与は、吸収が早く、より効果的であり、汚染やワクチン劣化のリスクを軽減します。現在販売されているワクチンの大半は、筋肉内注射または皮下注射で投与されており、これがこのセグメントの優位性を支えている。
疾患別では、ロタウイルスが2022年の世界ワクチン市場において高い市場シェアを占め、市場を支配している。

ロタウイルスは、世界中の乳幼児における重度の下痢や脱水の主な原因である。特に、清潔な水や医療資源へのアクセスが限られている低・中所得国では、相当数の入院や死亡の原因となっている。ロタウイルスに関連した疾病を予防することで、ワクチンは多くの命を救う可能性があり、国際保健機関にとって優先事項となっている。ロタウイルスに対するワクチン接種は、費用対効果の高い公衆衛生介入と考えられている。重症ロタウイルス感染症の治療には、入院や医療を含め、かなりの経済的負担がかかります。ワクチン接種は、個人にとっても医療システムにとっても、これらのコストを大幅に削減することができる。世界保健機関（WHO）や国連児童基金（UNICEF）などの組織は、子どもの健康を改善し、子どもの死亡率を世界的に減少させる取り組みの一環として、ロタウイルスワクチン接種を優先しています。ロタウイルスを含む下痢性疾患は、公衆衛生上の大きな課題となっています。ロタウイルスワクチンは、ロタウイルスに関連した病気を予防するだけでなく、小児の罹患率と死亡率の主な原因である下痢性疾患の全体的な負担軽減にも貢献します。多くの国では、ロタウイルスワクチン接種を国の予防接種プログラムに組み込んでおり、多くの場合、ワクチンを無料または割引価格で提供している。このような推奨や助成により、ワクチン接種率が向上しています。いくつかのロタウイルスワクチンが入手可能で、各国で使用が承認されている。これらのワクチンはさまざまな製造業者によって製造されており、入手しやすく、入手可能であることに貢献しています。ワクチン接種率が高ければ、群衆免疫につながり、地域社会におけるロタウイルスの全体的な感染を減少させ、ワクチンを接種できない乳幼児など、ワクチンを接種できない人々も守ることができます。ロタウイルスワクチンの分野における継続的な研究により、より効果的で手ごろな価格のワクチンが開発され、世界のワクチン市場におけるロタウイルスワクチンの役割をさらに後押ししています。ワクチンは一価と多価に分類される。一価ワクチンは、マラリア、エボラ出血熱、デング熱などの単一疾患と闘うために設計されている。多価ワクチンは、DTP、ポリオ、肝炎など複数の病気の予防接種に使用される。マラリアやエボラ出血熱などの流行が拡大していることが、一価ワクチンの需要を押し上げている。エボラ出血熱の大流行で予防接種が受けられなかったことから、医療機関は一価ワクチンの研究開発活動を活発化させている。

病院薬局は、2022年の世界ワクチン市場においてより高い市場シェアを獲得するため、流通チャネルのセグメンテーションに基づくワクチンの主要供給源となっている。

病院は患者にとって利用しやすい医療施設であるため、様々な理由で医療を受ける際にワクチンを接種するのに便利である。患者は、他の病状や定期検診のために病院を受診する際にワクチンを接種することがあります。多くの病院、特に大きな病院では、予防接種プログラムやクリニックを設立し、入院患者と外来患者の両方に幅広い種類のワクチンを提供している。こうしたプログラムは、小児、成人、特定の病状を持つ人など、さまざまな患者集団を対象としていることが多い。病院は、疾病の流行やパンデミック時の緊急対応に欠かせない存在である。公衆衛生上の緊急事態の際、病院は医療従事者、第一応答者、高リスク者へのワクチン投与において中心的な役割を果たします。病院は通常、推奨される温度と湿度でワクチンを保管するために必要なインフラと設備を持っています。適切な保管と取り扱いは、ワクチンの有効性を維持するために極めて重要であり、病院はこの目的のためのプロトコルを確立しています。病院は、薬剤師、看護師、医師を含む多くの医療専門家を雇用しており、彼らはワクチンを安全に投与し、予防接種に関する必要な情報を患者に提供するための訓練を受けています。病院の薬局は、入院患者にワクチンを投与することができ、特に特定の病状や外科的処置に関連するワクチンについては、入院中に必要な予防接種を受けることができます。病院は、公衆衛生機関や地域の保健局と協力して、予防接種キャンペーンを推進することが多い。また、地域全体の予防接種活動において、病院が予防接種会場となることもある。病院は通常、小児用定期接種ワクチン、成人用ワクチン、旅行用ワクチン、特定疾患用ワクチンなど、幅広い種類のワクチンを在庫している。このような多様性により、病院は患者集団の多様な医療ニーズに対応することができます。病院薬局は厳格な品質保証と安全基準を遵守し、ワクチンが安全かつ正確に投与されることを保証します。このような品質管理は、ワクチン接種プロセスに対する国民の信頼に貢献しています。病院は、ワクチン投与に対する償還プロセスを容易にする請求システムを確立しており、患者と医療施設の双方にとって経済的に実現可能です。

市場促進要因

- パンデミックへの備え：COVID-19パンデミックは、ワクチン研究開発への投資拡大のきっかけとなった。世界中の政府や組織が、かつてないペースでワクチン開発の緊急性を認識している。この危機感の高まりが、規制プロセスの合理化、共同研究、ワクチン製造能力への投資につながっている。さらに、ワクチン接種の重要性に対する一般市民の意識は急上昇しており、これは他の疾病のワクチン普及に長期的な好影響をもたらす可能性がある。

- 技術の進歩：COVID-19ワクチンに代表されるように、mRNAやベクターベースのワクチンプラットフォームが注目を集めている。これらのプラットフォームは迅速なワクチン開発と製造を可能にし、その期間を数年から数ヶ月に短縮する。さらに、マイクロニードルパッチや点鼻スプレーなどのワクチン送達方法の革新により、ワクチンへのアクセスや投与が向上している。ワクチン研究における人工知能と機械学習の統合も、候補となりうる物質をより効率的に特定するのに役立っている。

市場の課題

- ワクチン躊躇：ワクチン接種のためらいは依然として複雑な課題であり、誤った情報、医療制度への不信感、宗教的・文化的信条などの要因に影響される。ソーシャルメディア・プラットフォームは、ワクチンの誤情報の拡散に重要な役割を果たしている。この課題を克服するには、公衆衛生キャンペーン、正確な情報発信、医療従事者や地域社会を巻き込んだ信頼醸成活動など、多方面にわたる戦略が必要である。

- アクセスと公平性：世界中でワクチンへの公平なアクセスを確保することは、現在進行中の課題である。高所得国ほどワクチンの供給が容易であることが多く、低所得国は不利な立場に置かれている。COVAXのようなイニシアチブは、この不均衡に対処することを目的としているが、サプライチェーンの混乱、輸出規制、ワクチンのナショナリズムが進展を妨げることがある。長期的な解決策としては、技術移転、現地でのワクチン生産能力の構築、公平なワクチン配布のための国際協力が必要である。

市場動向

- デジタル化とデータ統合：デジタル・ツールは、ワクチンの流通とモニタリングを変革しつつある。ワクチン・パスポートやデジタル健康記録は、個人のワクチン接種状況の証明を可能にし、海外旅行や特定のサービスへのアクセスを容易にする。リアルタイムのデータ解析は、保健当局がワクチン接種率を追跡し、十分なサービスを受けていない地域を特定し、アウトブレイクに迅速に対応するのに役立っている。こうした傾向は、ワクチン接種プログラムの透明性と説明責任を高める。

- 新興感染症：新興感染症の脅威は、引き続きワクチン開発の原動力となっている。COVID-19のワクチン開発スピードの速さは、ワクチン・プラットフォームの適応性を実証した。メーカー各社は、新しい病原体に迅速に対応できる汎用性の高いプラットフォームに投資しており、将来のアウトブレイクへの対応時間を短縮している。政府や組織もまた、将来のパンデミックに備え、ワクチンや治療薬を備蓄している。

競合他社の状況

グラクソ・スミスクライン社、サノフィ社、ファイザー社、メルク社などの上位企業が市場の大半を占めている。これらの企業は強力な製品ポートフォリオを有し、戦略的な意思決定が可能で、ワクチン接種による複雑な疾患の根絶というアンメット・ニーズの解決に注力している。例えば、ファイザーのPrevnar 13やサノフィのポリオ／百日咳／Hibといった有望製品が市場をリードしている。絶え間ない徹底した研究開発の結果、世界中で新規製品が承認・上市されており、市場での地位維持が期待されている。さらに、ウイルス性疾患だけでなく細菌性疾患に対する注射剤の需要も増加していることから、ヒト産業における企業の成長と市場価値の向上が期待されている。同市場に名を連ねる主要企業には、Merck & Co., Inc.、BioNTech SE、Bavarian Nordic、GlaxoSmithKline PLC、Bharat Biotech International Limited、CSL、Charles River Laboratories、Creative Biogene、Daiichi Sankto Company Ltd.、Emergent BioSolutions Inc.サノフィ、セラム・インスティテュート・オブ・インディア、シノバック、アストラゼネカ、ノババックス、オックスフォード・バイオメディカ、ファイザー、武田薬品工業、イノビオ・ファーマシューティカル、ウォルバックス・バイオテクノロジーなど。

主要開発

- 2021年9月、インド血清研究所は、アストラゼネカからライセンス供与を受けたCovishieldを皮切りに、毎四半期少なくとも1種類のワクチンを上市する予定である。

- 2021年、アボット社はインドで、4つのウイルス株に対する予防効果を持つ新しいインフルエンザ用不活化4価ワクチンを発売。

- 2021年、グラクソ・スミスクライン・ピーエルシーは、実験的ワクチンPRIORIXの生物製剤承認申請（BLA）をUSFDAに提出したと発表した。当初ドイツで登録されたこのワクチンは、最近100カ国以上で承認された。

- 2021年、メルク・シャープ・アンド・ドームの完全子会社であるMSDファーマシューティカルズは、インド初の性別を問わないHPVワクチンであるガーダシル9を発売した。

本レポートで検討

- 地域グローバル
- 歴史的な年2017
- 基準年2022
- 推定年2023
- 予測年2028

本レポートでカバーされている側面

- 世界のワクチン市場の展望とその価値とセグメント別予測
- 地域別・国別の変圧器市場分析
- 様々な促進要因と課題
- 進行中のトレンドと開発
- トップ企業のプロファイル
- 戦略的提言

レポート対象地域と国

- 北米（米国、カナダ、メキシコ）
- ヨーロッパ（ドイツ、イギリス、フランス、スペイン、イタリア、ロシア）
- アジア太平洋（中国、日本、インド、オーストラリア、韓国）
- 南米（ブラジル、アルゼンチン、コロンビア）
- 中東・アフリカ（UAE、サウジアラビア、南アフリカ）

技術別

- 混合ワクチン
- 不活化・サブユニットワクチン
- 不活化ワクチン
- 組み換えワクチン
- トキソイドワクチン
- ウイルスベクターワクチン
- その他

投与経路別

- 筋肉内および皮下投与
- 経口投与
- その他

エンドユーザー別

- 小児科
- 成人

疾患別

- 肺炎球菌感染症
- がん
- インフルエンザ
- ロタウイルス
- ジフテリア、百日咳、破傷風（DTP）
- ヒト乳頭腫ウイルス（HPV）
- 帯状疱疹
- 髄膜炎菌感染症
- 肝炎
- 水痘（水ぼうそう）
- 流行性耳下腺炎
- その他

タイプ別

- 一価ワクチン
- 多価ワクチン

流通チャネル別

- 病院薬局
- 小売薬局
- オンライン薬局
- その他

レポートのアプローチ

本レポートは、一次調査と二次調査を組み合わせたアプローチで構成されています。当初は、市場を理解し、市場に存在する企業をリストアップするために二次調査を行った。二次調査は、プレスリリースや企業の年次報告書などの第三者情報源、政府が作成した報告書やデータベースの分析で構成されている。二次情報源からデータを収集した後、一次調査は、市場がどのように機能しているかについて主要プレーヤーに電話インタビューを行い、市場のディーラーや流通業者と取引コールを行うことによって実施された。その後、消費者を地域別、階層別、年齢層別、性別に均等にセグメンテーションし、消費者への一次調査を開始した。一次データを入手した後は、二次ソースから入手した詳細の検証を開始した。

対象読者

本レポートは、業界コンサルタント、メーカー、サプライヤー、ドローン業界関連団体・組織、政府機関、その他関係者が市場中心の戦略を立てる際にお役立ていただけます。また、マーケティングやプレゼンテーションだけでなく、業界に関する競合知識を高めることもできます。










***注：ご注文確認後、報告書をお届けするまでに48時間（2営業日）かかります。

ページTOPに戻る


目次

Table of Contents
1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Covid-19 Effect
2.5. Supply chain Analysis
2.6. Policy & Regulatory Framework
2.7. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Vaccines Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Technology
6.5. Market Size and Forecast, By End-User
6.6. Market Size and Forecast, By Distribution Channel
6.7. Market Size and Forecast, By Type
6.8. Market Size and Forecast, By Route of Administration
6.9. Market Size and Forecast, By Disease
7. North America Vaccines Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Technology
7.4. Market Size and Forecast, By End-User
7.5. Market Size and Forecast, By Distribution Channel
7.6. Market Size and Forecast, By Type
7.7. Market Size and Forecast, By Route of Administration
7.8. Market Size and Forecast, By Disease
7.9. United States Vaccines Market Outlook
7.9.1. Market Size By Value
7.9.2. Market Size and Forecast By Technology
7.9.3. Market Size and Forecast By End-User
7.9.4. Market Size and Forecast By Distribution Channel
7.10. Canada Vaccines Market Outlook
7.10.1. Market Size By Value
7.10.2. Market Size and Forecast By Technology
7.10.3. Market Size and Forecast By End-User
7.10.4. Market Size and Forecast By Distribution Channel
7.11. Mexico Vaccines Market Outlook
7.11.1. Market Size By Value
7.11.2. Market Size and Forecast By Technology
7.11.3. Market Size and Forecast By End-User
7.11.4. Market Size and Forecast By Distribution Channel
8. Europe Vaccines Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Technology
8.4. Market Size and Forecast, By End-User
8.5. Market Size and Forecast, By Distribution Channel
8.6. Market Size and Forecast, By Type
8.7. Market Size and Forecast, By Route of Administration
8.8. Market Size and Forecast, By Disease
8.9. Germany Vaccines Market Outlook
8.9.1. Market Size By Value
8.9.2. Market Size and Forecast By Technology
8.9.3. Market Size and Forecast By End-User
8.9.4. Market Size and Forecast By Distribution Channel
8.10. United Kingdom Vaccines Market Outlook
8.10.1. Market Size By Value
8.10.2. Market Size and Forecast By Technology
8.10.3. Market Size and Forecast By End-User
8.10.4. Market Size and Forecast By Distribution Channel
8.11. France Vaccines Market Outlook
8.11.1. Market Size By Value
8.11.2. Market Size and Forecast By Technology
8.11.3. Market Size and Forecast By End-User
8.11.4. Market Size and Forecast By Distribution Channel
8.12. Italy Vaccines Market Outlook
8.12.1. Market Size By Value
8.12.2. Market Size and Forecast By Technology
8.12.3. Market Size and Forecast By End-User
8.12.4. Market Size and Forecast By Distribution Channel
8.13. Spain Vaccines Market Outlook
8.13.1. Market Size By Value
8.13.2. Market Size and Forecast By Technology
8.13.3. Market Size and Forecast By End-User
8.13.4. Market Size and Forecast By Distribution Channel
8.14. Russia Vaccines Market Outlook
8.14.1. Market Size By Value
8.14.2. Market Size and Forecast By Technology
8.14.3. Market Size and Forecast By End-User
8.14.4. Market Size and Forecast By Distribution Channel
9. Asia-Pacific Vaccines Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Technology
9.4. Market Size and Forecast, By End-User
9.5. Market Size and Forecast, By Distribution Channel
9.6. Market Size and Forecast, By Type
9.7. Market Size and Forecast, By Route of Administration
9.8. Market Size and Forecast, By Disease
9.9. China Vaccines Market Outlook
9.9.1. Market Size By Value
9.9.2. Market Size and Forecast By Technology
9.9.3. Market Size and Forecast By End-User
9.9.4. Market Size and Forecast By Distribution Channel
9.10. Japan Vaccines Market Outlook
9.10.1. Market Size By Value
9.10.2. Market Size and Forecast By Technology
9.10.3. Market Size and Forecast By End-User
9.10.4. Market Size and Forecast By Distribution Channel
9.11. India Vaccines Market Outlook
9.11.1. Market Size By Value
9.11.2. Market Size and Forecast By Technology
9.11.3. Market Size and Forecast By End-User
9.11.4. Market Size and Forecast By Distribution Channel
9.12. Australia Vaccines Market Outlook
9.12.1. Market Size By Value
9.12.2. Market Size and Forecast By Technology
9.12.3. Market Size and Forecast By End-User
9.12.4. Market Size and Forecast By Distribution Channel
9.13. South Korea Vaccines Market Outlook
9.13.1. Market Size By Value
9.13.2. Market Size and Forecast By Technology
9.13.3. Market Size and Forecast By End-User
9.13.4. Market Size and Forecast By Distribution Channel
10. South America Vaccines Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Technology
10.4. Market Size and Forecast, By End-User
10.5. Market Size and Forecast, By Distribution Channel
10.6. Market Size and Forecast, By Type
10.7. Market Size and Forecast, By Route of Administration
10.8. Market Size and Forecast, By Disease
10.9. Brazil Vaccines Market Outlook
10.9.1. Market Size By Value
10.9.2. Market Size and Forecast By Technology
10.9.3. Market Size and Forecast By End-User
10.9.4. Market Size and Forecast By Distribution Channel
10.10. Argentina Vaccines Market Outlook
10.10.1. Market Size By Value
10.10.2. Market Size and Forecast By Technology
10.10.3. Market Size and Forecast By End-User
10.10.4. Market Size and Forecast By Distribution Channel
10.11. Columbia Vaccines Market Outlook
10.11.1. Market Size By Value
10.11.2. Market Size and Forecast By Technology
10.11.3. Market Size and Forecast By End-User
10.11.4. Market Size and Forecast By Distribution Channel
11. Middle East & Africa Vaccines Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Technology
11.4. Market Size and Forecast, By End-User
11.5. Market Size and Forecast, By Distribution Channel
11.6. Market Size and Forecast, By Type
11.7. Market Size and Forecast, By Route of Administration
11.8. Market Size and Forecast, By Disease
11.9. UAE Vaccines Market Outlook
11.9.1. Market Size By Value
11.9.2. Market Size and Forecast By Technology
11.9.3. Market Size and Forecast By End-User
11.9.4. Market Size and Forecast By Distribution Channel
11.10. Saudi Arabia Vaccines Market Outlook
11.10.1. Market Size By Value
11.10.2. Market Size and Forecast By Technology
11.10.3. Market Size and Forecast By End-User
11.10.4. Market Size and Forecast By Distribution Channel
11.11. South Africa Vaccines Market Outlook
11.11.1. Market Size By Value
11.11.2. Market Size and Forecast By Technology
11.11.3. Market Size and Forecast By End-User
11.11.4. Market Size and Forecast By Distribution Channel
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2022
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Merck & Co., Inc
12.6.2. BioNTech SE
12.6.3. Bavarian Nordic
12.6.4. GlaxoSmithKline PLC
12.6.5. Bharat Biotech International Limited
12.6.6. CSL
12.6.7. Charles River Laboratories
12.6.8. Creative Biogene
12.6.9. Daiichi Sankto Company Ltd
12.6.10. Emergent BioSolutions Inc.
12.6.11. Sanofi S.A
12.6.12. Serum Institute of India Pvt. Ltd
12.6.13. Sinovac
12.6.14. AstraZeneca plc
12.6.15. Novavax
12.6.16. Oxford Biomedica
12.6.17. Pfizer Inc
12.6.18. Takeda Pharmaceutical Company Limited
12.6.19. Inovio Pharmaceutical
12.6.20. Walvax Biotechnology Co., Ltd.
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
14.3. Related Reports
15. Disclaimer

List of Figures
Figure 1: Global Vaccines Market Size (USD Billion) By Region, 2022 & 2028
Figure 2: Market attractiveness Index, By Region 2028
Figure 3: Market attractiveness Index, By Segment 2028
Figure 4: Global Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 5: Global Vaccines Market Share By Region (2022)
Figure 6: North America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 7: North America Vaccines Market Share By Country (2022)
Figure 8: US Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 9: Canada Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 10: Mexico Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 11: Europe Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 12: Europe Vaccines Market Share By Country (2022)
Figure 13: Germany Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 14: UK Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 15: France Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 16: Italy Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 17: Spain Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 18: Russia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 19: Asia-Pacific Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 20: Asia-Pacific Vaccines Market Share By Country (2022)
Figure 21: China Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 22: Japan Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 23: India Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 24: Australia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 25: South Korea Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 26: South America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 27: South America Vaccines Market Share By Country (2022)
Figure 28: Brazil Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 29: Argentina Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 30: Columbia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 31: Middle East & Africa Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 32: Middle East & Africa Vaccines Market Share By Country (2022)
Figure 33: UAE Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 34: Saudi Arabia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 35: South Africa Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 36: Competitive Dashboard of top 5 players, 2022
Figure 37: Market Share insights of key players, 2022
Figure 38: Porter's Five Forces of Global Vaccines Market

List of Table
Table 1 : Global Vaccines Market Snapshot, By Segmentation (2022 & 2028) (in USD Billion)
Table 2 : Influencing Factors for Vaccines Market, 2022
Table 3: Top 10 Counties Economic Snapshot 2020
Table 4: Economic Snapshot of Other Prominent Countries 2020
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Vaccines Market Size and Forecast, By Geography (2017 to 2028F) (In USD Billion)
Table 7 : Global Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 8 : Global Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 9 : Global Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 10 : Global Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 11 : Global Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 12 : Global Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 13 : North America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 14 : North America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 15 : North America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 16 : North America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 17 : North America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 18 : North America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 19 : United States Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 20 : United States Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 21 : United States Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 22 : Canada Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 23 : Canada Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 24 : Canada Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 25 : Mexico Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 26 : Mexico Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 27 : Mexico Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 28 : Europe Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 29 : Europe Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 30 : Europe Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 31 : Europe Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 32 : Europe Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 33 : Europe Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 34 : Germany Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 35 : Germany Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 36 : Germany Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 37 : United Kingdom Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 38 : United Kingdom Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 39 : United Kingdom Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 40 : France Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 41 : France Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 42 : France Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 43 : Italy Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 44 : Italy Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 45 : Italy Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 46 : Spain Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 47 : Spain Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 48 : Spain Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 49 : Russia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 50 : Russia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 51 : Russia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 52 : Asia-Pacific Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 53 : Asia-Pacific Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 54 : Asia-Pacific Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 55 : Asia-Pacific Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 56 : Asia-Pacific Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 57 : Asia Pacific Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 58 : China Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 59 : China Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 60 : China Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 61 : Japan Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 62 : Japan Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 63 : Japan Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 64 : India Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 65 : India Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 66 : India Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 67 : Australia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 68 : Australia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 69 : Australia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 70 : South Korea Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 71 : South Korea Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 72 : South Korea Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 73 : South America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 74 : South America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 75 : South America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 76 : South America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 77 : South America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 78 : South America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 79 : Brazil Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 80 : Brazil Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 81 : Brazil Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 82 : Argentina Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 83 : Argentina Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 84 : Argentina Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 85 : Colombia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 86 : Colombia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 87 : Colombia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 88 : Middle East & Africa Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 89 : Middle East & Africa Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 90 : Middle East & Africa Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 91 : Middle East & Africa Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 92 : Middle East & Africa Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 93 : Middle East & Africa Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 94 : United Arab Emirates Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 95 : United Arab Emirates Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 96 : United Arab Emirates Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 97 : Saudi Arabia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 98 : Saudi Arabia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 99 : Saudi Arabia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 100 : South Africa Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 101 : South Africa Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 102 : South Africa Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)

　

ページTOPに戻る


　

Summary

Vaccines are the most powerful and cost-effective way to protect Billions of people around the world. Vaccine development has the potential to transform health by eliminating the burden of life-threatening infectious diseases among the population of the affluent nations. World Health Organization (WHO) states that immunization awareness and government initiatives have helped prevent 2-3 million deaths annually. Greater investments coupled with merging and partnerships of companies are boosting the production and sales of products globally. The vaccines market outlook states that the rising incidence of diseases worldwide is encouraging the adoption of vaccines, thereby creating prospects for the growth of the vaccines market. Deadly diseases such as tuberculosis, cancer, influenza, and pneumonia have high fatality rates, which is compelling people to opt for vaccinations. For instance, as per the World Health Organization (WHO), around 1.5 million people died from tuberculosis in 2020 while over 10 million people fell ill with TB. Additionally, increasing public awareness about the benefits of vaccination along with rising government support in research and development is likely to act as a catalyst for the growth of the vaccines market. Factors such as the rising prevalence of chronic and infectious diseases, increase in immunization programs, advancements in vaccine technology, and changing attitudes towards vaccines are some of the key factors expected to drive the growth in the vaccines market during the forecast period. The rising need for protecting children from deadly chronic and infectious diseases like tuberculosis, cancer, hepatitis, influence, etc. is expected to create lucrative opportunities for vaccine manufacturers during the forecast period. According to the United Nations Children’s Fund (UNICEF), each year vaccination saves over 3 Million children from deadly diseases. One of the biggest challenges faced by organizations and companies around the world is the ongoing trial and error for effective fight against diseases such as malaria, HIV, and tuberculosis. Government and pharmaceutical companies are making enormous efforts in establishing arrangements for the development of products for such diseases. Additionally, increasing prevalence of endemic and infectious diseases is anticipated to propel the vaccines market growth during the forecast period.

According to the research report, “Global Vaccine Market Outlook, 2028” published by Bonafide Research, the market is anticipated to cross USD 105 Billion by 2028, increasing from USD 68.22 Billion in 2022. The market is expected to grow with 7.81% CAGR by 2023-28. Governments investing huge capital in progressive healthcare systems are anticipated to expand the vaccine market size. Government healthcare programs deliver vaccines to infants to provide them with prevention from chronic diseases like tuberculosis, rotavirus, etc. The rise in new diseases like H1B1 infection, and swine flu (H1N1) is pushing the authorities to adopt new methods that help in preventing the diseases. For instance, in June, 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. In addition, rise in incidence of various infectious diseases and growth in awareness regarding early disease diagnosis & prevention drive the demand for protective vaccines; thereby, boosting the vaccines market growth. Rise in the demand for vaccines owing to high incidences of diseases worldwide which drive the market growth. The World Health Organization (WHO) estimates the around 325 million people, or nearly 4% of the world population, live with viral hepatitis. In addition, the advancements in vaccine technology are providing an opportunity to target new diseases support the market growth. There has been a development of a wide array of new vaccination technologies ranging from targeted attenuation techniques of live pathogens to the delivery of biologically engineered protein and peptide antigens as well as viral vector and nucleic-acid based antigens. Most of these technologies have highly promising results. Thus, there has been a significant increase in spending for the development of vaccine technology which propels the market growth.

Rapidly evolving technology has a profound impact on vaccine market trends. Developments like the introduction of genetic engineering and lab automation are helping vaccine manufacturers to develop low-cost vaccines, which may attract markets and eventually enable vaccine market access. Additionally, various initiatives taken by governments of emerging nations for launching mass vaccination drives may augment the overall vaccines industry worth in the future. The development of vaccines is a lengthy, complicated, and expensive process. As a result, most of the vaccines are usually costlier, which is acting as a key hurdle in the growth of the vaccines market. Similarly, lack of awareness and poor healthcare infrastructure across developing regions has also hampered vaccine market access. Vaccine manufacturing giants like Pfizer and GSK are vigorously investing in vaccine research and development for introducing new products with a highly effective nature. Besides this, they are holding various trials for establishing the safety and efficacy of vaccines. For instance, in January 2022, Pfizer Inc., and BioNTech SE initiated a clinical study to evaluate the safety, immunogenicity, and tolerability of an Omicron-based vaccine candidate in adults aged 18 to 55. The market is anticipated to thrive at a significant CAGR between 2022 and 2028. Also, the increasing understanding of emerging diseases has led to the development of numerous vaccines during the past years. The availability of efficient vaccines for influenza, DTP, as well as pancreatic cancer has driven the market growth. Furthermore, advancements in the technology helped to achieve milestones in the vaccine development including avian flu vaccine, nasal flu vaccine, therapeutic cancer vaccine and egg-free vaccine among others. Along with development and disease prevalence, the immunization programs, and supportive initiatives by the government authorities to improve immunization coverage will positively impact the vaccines industry landscape during the analysis period.

Based on the regions, North America is leading the global vaccine market with more than 35% market share in 2022.

North America is home to some of the world’s largest and most influential pharmaceutical companies, including Pfizer, Moderna, Johnson & Johnson, and Merck. These companies have the resources, expertise, and research infrastructure to develop and manufacture vaccines at scale. North American companies have a long history of investing in research and development (R&D) for vaccines. This has allowed them to be at the forefront of vaccine innovation, including the development of mRNA vaccines, which gained prominence during the COVID-19 pandemic. The United States, in particular, has a well-established regulatory framework for approving and monitoring vaccines. The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of vaccines, which can boost confidence in their products globally. North American pharmaceutical companies often have access to significant financial resources, including private and public funding, which can support the development and production of vaccines. The region has a robust infrastructure for vaccine manufacturing, with numerous facilities capable of producing large quantities of vaccines efficiently. North America also benefits from well-established distribution networks and logistics infrastructure, which are critical for the timely delivery of vaccines, both domestically and internationally. North American pharmaceutical companies often collaborate with international organizations, governments, and non-profit organizations to expand access to vaccines in low- and middle-income countries. The healthcare sector is expected to witness significant growth in the region following the heavy investments by the government and several market players. Moreover, the robust healthcare infrastructure and research centers have heavily contributed to saving millions of lives. In the U.S. alone, vaccines have prevented over 21 million hospitalizations and 732,000 deaths among children born in the last 20 years, CDC. Apart from this, technological advancements are boosting the growth of vaccines market in the region. Recently, in October 2018, the U.S. FDA has agreed to consider the application of ‘Dengvaxia’—a first licensed vaccine against dengue by Sanofi Pasteur. The U.S. Virgin Islands, Puerto Rico, and Guam are some of the regions with the highest prevalence of dengue across the U.S.

Based on the technology, conjugate vaccines are projected to lead the market during the forecast period with higher revenue generation in global vaccine market.

The global vaccine market is segmented into various technology types including conjugate vaccines, inactivated & subunit vaccines, live attenuated vaccines, recombinant vaccines and toxoid vaccines. The conjugate vaccines segment accounted for the leading share of the global vaccine market by vaccine type due to increased spending by government and private companies on its development. Rising preference for conjugate vaccines is due to their various additional features including greater antibody persistence and avidity. Conjugate vaccines are designed to address pathogens with polysaccharide capsules, such as certain bacteria. Polysaccharide capsules can be poorly immunogenic in infants and young children. Conjugate vaccines overcome this limitation by attaching the polysaccharides to carrier proteins, making them more immunogenic. This results in a stronger and more durable immune response, particularly in vulnerable populations. Many conjugate vaccines target bacteria that cause severe and potentially life-threatening diseases, such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcus), and Neisseria meningitidis (meningococcus). These vaccines have significantly reduced the incidence of these diseases, leading to improved public health outcomes. Conjugate vaccines are suitable for a broader age range, including infants, young children, and adults. This versatility allows for comprehensive vaccination programs and the protection of individuals across different age groups. Conjugate vaccines not only protect vaccinated individuals but also contribute to herd immunity. By reducing the prevalence of a pathogen in the population, even those who are not vaccinated benefit from decreased transmission rates, reducing their risk of infection. Conjugate vaccines against meningococcus and pneumococcus have been particularly successful in preventing meningitis and pneumonia, two severe and potentially deadly infections. Many countries have implemented successful immunization campaigns using conjugate vaccines, leading to a substantial reduction in vaccine-preventable diseases. These campaigns often target children and adolescents, who are at higher risk of certain bacterial infections. Conjugate vaccines are recommended by leading health authorities, including the World Health Organization (WHO) and national health agencies, due to their proven effectiveness and safety profile.

Intramuscular and subcutaneous route of administration for vaccines have grown with higher market growth throughout the historic time period in global vaccine market.

The intramuscular and subcutaneous administration segment accounted for the largest share of the market (excluding COVID-19 vaccines). Benefits such as, administration rate, precise control of dose and ease of administration makes the Intramuscular & Subcutaneous as one of the most prevalent route and thus drives the market. The segment is projected to witness higher market growth owing to benefits associated with it such as a low rate of reaction on injection sites and higher immune response compared to other routes of administration. The intramuscular injections are administered into muscles and subcutaneous injections are injected into the underneath skin and fat layer. Intramuscular injections are administrated for Hepatitis A, Hepatitis B, IPV, HPV, PCV-7, Hib, and influenza. However, the oral administration segment is expected to grow with significant CAGR during the forecast period. The advantages of orally administered vaccines such as elicitation of both mucosal and systemic immunities and elimination of injection-associated adverse events are a few factors driving market growth. Polio vaccine, rotavirus vaccine, and other such pediatric vaccines are generally administered via the oral route. Furthermore, on the basis of end user, the vaccines market is segmented into pediatric and adult users. The pediatric users segment accounted for the largest share of the market (excluding COVID 19 vaccines), while the adult user segment is estimated to register the highest CAGR during the forecast period. Factors such as, growing government initiatives and growing company initiatives to develop advanced pediatric vaccines for preventing diseases are expected to drive market growth for pediatric vaccines. Parenteral administration is highly preferred for administering vaccines and hence the segment dominated the vaccine market. Parenteral administration provides faster absorption, is more effective, and reduces the risk of contamination and vaccine degradation. Amongst the currently marketed vaccines, a wide majority are administered as either intramuscular or subcutaneous injections, which contributes to the segments’ dominance.
Based on the disease, Rotavirus is dominating the market in 2022 with higher market share in global vaccine market as these infections are a major contributor to child mortality, especially in regions with high disease prevalence.

Rotavirus is a leading cause of severe diarrhea and dehydration in infants and young children worldwide. It is responsible for a substantial number of hospitalizations and deaths, particularly in low- and middle-income countries where access to clean water and healthcare resources may be limited. By preventing rotavirus-related illnesses, vaccines have the potential to save numerous lives, making them a priority for global health organizations. Vaccination against rotavirus is considered a cost-effective public health intervention. The financial burden of treating severe rotavirus infections, including hospitalization and medical care, is substantial. Vaccination can significantly reduce these costs, both for individuals and healthcare systems. Organizations like the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) have prioritized rotavirus vaccination as part of their efforts to improve child health and reduce child mortality globally. Diarrheal diseases, including those caused by rotavirus, pose a substantial public health challenge. Rotavirus vaccines not only prevent rotavirus-related illness but also contribute to reducing the overall burden of diarrheal diseases, which is a leading cause of childhood morbidity and mortality. Many countries have incorporated rotavirus vaccination into their national immunization programs, often providing the vaccine for free or at a reduced cost. These recommendations and subsidies increase vaccine uptake. Several rotavirus vaccines are available and have been approved for use in various countries. These vaccines are produced by different manufacturers, contributing to their accessibility and availability. High vaccine coverage can lead to herd immunity, reducing the overall transmission of the rotavirus in communities and protecting even those who may not be vaccinated, such as infants too young to receive the vaccine. Ongoing research in the field of rotavirus vaccines has led to the development of more effective and affordable vaccines, further supporting their role in the global vaccine market. Vaccines can be categorized into monovalent and multivalent. Monovalent are designed to combat single diseases like malaria, Ebola, and dengue. Multivalent is used in the immunization of multiple diseases, including DTP, polio, and hepatitis. The growing prevalence of malaria, Ebola and others are driving the demand for monovalent vaccines. Ebola outbreak with no vaccination available has prompted the healthcare organizations to increase the research and development activities of monovalent vaccines.

Hospital pharmacy have become the major source of vaccines based on distribution channel segmentations owing to higher market share in 2022 in global vaccine market.

Hospitals are accessible healthcare facilities for patients, making it convenient for individuals to receive vaccines when seeking medical care for various reasons. Patients may receive vaccines during hospital visits for other medical conditions or for routine check-ups. Many hospitals, especially larger ones, have established immunization programs and clinics that offer a wide range of vaccines to both inpatients and outpatients. These programs often target various patient populations, including children, adults, and individuals with specific medical conditions. Hospitals are critical components of emergency response efforts during disease outbreaks and pandemics. During public health emergencies, hospitals play a central role in administering vaccines to healthcare workers, first responders, and high-risk individuals. Hospitals typically have the infrastructure and equipment necessary to store vaccines at the recommended temperature and humidity levels. Proper storage and handling are crucial to maintaining vaccine efficacy, and hospitals have well-established protocols for this purpose. Hospitals employ a large number of healthcare professionals, including pharmacists, nurses, and doctors, who are trained to administer vaccines safely and provide patients with the necessary information about immunization. Hospital pharmacies can administer vaccines to patients admitted to the hospital, ensuring that individuals receive necessary vaccinations during their stay, particularly for vaccines related to specific medical conditions or surgical procedures. Hospitals often collaborate with public health agencies and local health departments to promote vaccination campaigns. They may serve as vaccination sites during community-wide immunization efforts. Hospitals typically stock a wide range of vaccines, including routine childhood vaccines, adult vaccines, travel vaccines, and vaccines for specific medical conditions. This diversity allows hospitals to meet the diverse healthcare needs of their patient population. Hospital pharmacies adhere to strict quality assurance and safety standards, ensuring that vaccines are administered safely and accurately. This quality control contributes to public confidence in the vaccination process. Hospitals have established billing systems that can facilitate the reimbursement process for vaccine administration, making it financially feasible for both patients and the healthcare facility.

Market Drivers

• Pandemic Preparedness: The COVID-19 pandemic has been a catalyst for increased investment in vaccine research and development. Governments and organizations worldwide have recognized the urgency of developing vaccines at an unprecedented pace. This heightened sense of urgency has led to streamlined regulatory processes, collaborative research efforts, and investments in vaccine manufacturing capacity. Moreover, public awareness of the importance of vaccination has surged, which can have long-term positive effects on vaccine adoption for other diseases.

• Technological Advancements: mRNA and vector-based vaccine platforms, as exemplified by the COVID-19 vaccines, have gained prominence. These platforms allow for rapid vaccine development and production, reducing the timeline from years to months. Additionally, innovations in vaccine delivery methods, such as microneedle patches and nasal sprays, are enhancing vaccine accessibility and administration. The integration of artificial intelligence and machine learning in vaccine research is also helping identify potential candidates more efficiently.

Market Challenges

• Vaccine Hesitancy: Vaccine hesitancy remains a complex challenge, influenced by factors like misinformation, distrust of healthcare systems, and religious or cultural beliefs. Social media platforms play a significant role in the spread of vaccine misinformation. Overcoming this challenge requires multi-pronged strategies, including public health campaigns, accurate information dissemination, and trust-building initiatives involving healthcare professionals and communities.

• Access and Equity: Ensuring equitable access to vaccines across the globe is an ongoing challenge. High-income countries often secure vaccine supplies more easily, leaving lower-income countries at a disadvantage. Initiatives like COVAX aim to address this imbalance, but supply chain disruptions, export restrictions, and vaccine nationalism can hinder progress. Long-term solutions involve technology transfer, local vaccine production capacity building, and international cooperation to distribute vaccines fairly.

Market Trends

• Digitalization and Data Integration: Digital tools are transforming vaccine distribution and monitoring. Vaccine passports and digital health records enable individuals to prove their vaccination status, facilitating international travel and access to certain services. Real-time data analytics help health authorities track vaccine coverage, identify underserved areas, and respond to outbreaks swiftly. These trends enhance transparency and accountability in vaccination programs.

• Emerging Infectious Diseases: The threat of emerging infectious diseases continues to drive vaccine development efforts. The speed at which vaccines were developed for COVID-19 demonstrated the adaptability of vaccine platforms. Manufacturers are investing in versatile platforms that can be quickly tailored to new pathogens, reducing the response time to future outbreaks. Governments and organizations are also stockpiling vaccines and therapeutics for potential future pandemics as part of their preparedness efforts.

Competitive Landscape

The top market players, such as GlaxoSmithKline plc, Sanofi, Pfizer Inc., and Merck & Co., Inc., account for the majority of the market. These companies have a strong product portfolio, the capability of strategic decisions, and focus on resolving the unmet needs in eradicating complex diseases through vaccination. For instance, potential products such as Prevnar 13 of Pfizer and Polio/Pertussis/Hib of Sanofi are leading in the market. Constant exhaustive R&D resulting in approvals and launches of novel products worldwide is expected to maintain their position in the market. Furthermore, increasing demand for injection doses for viral as well as bacterial diseases is anticipated to fuel the company growth and market value in the human industry. Major companies profiled in the market include Merck & Co., Inc, BioNTech SE, Bavarian Nordic, GlaxoSmithKline PLC, Bharat Biotech International Limited , CSL, Charles River Laboratories, Creative Biogene, Daiichi Sankto Company Ltd, Emergent BioSolutions Inc. , Sanofi S.A, Serum Institute of India Pvt. Ltd, Sinovac , AstraZeneca plc , Novavax, Oxford Biomedica, Pfizer Inc, Takeda Pharmaceutical Company Limited, Inovio Pharmaceutical and Walvax Biotechnology Co., Ltd.

Key Developments

• In September 2021, the Serum Institute of India planned to launch at least one vaccine every quarter beginning with Covishield, which is licensed from AstraZeneca.

• In 2021, Abbott launched a new inactivated quadrivalent vaccine for influenza in India that offers protection against four virus strains, in India.

• In 2021, GlaxoSmithKline plc announced that they submitted a Biologics License Application (BLA) to the USFDA for its experimental vaccination PRIORIX. Over 100 nations have recently granted licenses for the vaccine, initially registered in Germany.

• In 2021, MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme, launched Gardasil 9, India’s first gender-neutral HPV vaccine.

Considered in this report:

• Geography: Global
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Global Vaccines market Outlook with its value and forecast along with its segments
• Region & Country-wise Transformers market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Regions & Countries covered in the report

• North America (United States, Canada, Mexico)
• Europe (Germany, United Kingdom, France, Spain, Italy, Russia)
• Asia-Pacific (China, Japan, India, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle-East & Africa (UAE, Saudi Arabia, South Africa)

By Technology

• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration

• Intramuscular and subcutaneous administration
• Oral administration
• Others

By End-User Type

• Pediatrics
• Adults

By Disease

• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others

By Type

• Monovalent vaccines
• Multivalent vaccines

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.










***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.



ページTOPに戻る


Table of Contents

Table of Contents
1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Covid-19 Effect
2.5. Supply chain Analysis
2.6. Policy & Regulatory Framework
2.7. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Vaccines Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Technology
6.5. Market Size and Forecast, By End-User
6.6. Market Size and Forecast, By Distribution Channel
6.7. Market Size and Forecast, By Type
6.8. Market Size and Forecast, By Route of Administration
6.9. Market Size and Forecast, By Disease
7. North America Vaccines Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Technology
7.4. Market Size and Forecast, By End-User
7.5. Market Size and Forecast, By Distribution Channel
7.6. Market Size and Forecast, By Type
7.7. Market Size and Forecast, By Route of Administration
7.8. Market Size and Forecast, By Disease
7.9. United States Vaccines Market Outlook
7.9.1. Market Size By Value
7.9.2. Market Size and Forecast By Technology
7.9.3. Market Size and Forecast By End-User
7.9.4. Market Size and Forecast By Distribution Channel
7.10. Canada Vaccines Market Outlook
7.10.1. Market Size By Value
7.10.2. Market Size and Forecast By Technology
7.10.3. Market Size and Forecast By End-User
7.10.4. Market Size and Forecast By Distribution Channel
7.11. Mexico Vaccines Market Outlook
7.11.1. Market Size By Value
7.11.2. Market Size and Forecast By Technology
7.11.3. Market Size and Forecast By End-User
7.11.4. Market Size and Forecast By Distribution Channel
8. Europe Vaccines Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Technology
8.4. Market Size and Forecast, By End-User
8.5. Market Size and Forecast, By Distribution Channel
8.6. Market Size and Forecast, By Type
8.7. Market Size and Forecast, By Route of Administration
8.8. Market Size and Forecast, By Disease
8.9. Germany Vaccines Market Outlook
8.9.1. Market Size By Value
8.9.2. Market Size and Forecast By Technology
8.9.3. Market Size and Forecast By End-User
8.9.4. Market Size and Forecast By Distribution Channel
8.10. United Kingdom Vaccines Market Outlook
8.10.1. Market Size By Value
8.10.2. Market Size and Forecast By Technology
8.10.3. Market Size and Forecast By End-User
8.10.4. Market Size and Forecast By Distribution Channel
8.11. France Vaccines Market Outlook
8.11.1. Market Size By Value
8.11.2. Market Size and Forecast By Technology
8.11.3. Market Size and Forecast By End-User
8.11.4. Market Size and Forecast By Distribution Channel
8.12. Italy Vaccines Market Outlook
8.12.1. Market Size By Value
8.12.2. Market Size and Forecast By Technology
8.12.3. Market Size and Forecast By End-User
8.12.4. Market Size and Forecast By Distribution Channel
8.13. Spain Vaccines Market Outlook
8.13.1. Market Size By Value
8.13.2. Market Size and Forecast By Technology
8.13.3. Market Size and Forecast By End-User
8.13.4. Market Size and Forecast By Distribution Channel
8.14. Russia Vaccines Market Outlook
8.14.1. Market Size By Value
8.14.2. Market Size and Forecast By Technology
8.14.3. Market Size and Forecast By End-User
8.14.4. Market Size and Forecast By Distribution Channel
9. Asia-Pacific Vaccines Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Technology
9.4. Market Size and Forecast, By End-User
9.5. Market Size and Forecast, By Distribution Channel
9.6. Market Size and Forecast, By Type
9.7. Market Size and Forecast, By Route of Administration
9.8. Market Size and Forecast, By Disease
9.9. China Vaccines Market Outlook
9.9.1. Market Size By Value
9.9.2. Market Size and Forecast By Technology
9.9.3. Market Size and Forecast By End-User
9.9.4. Market Size and Forecast By Distribution Channel
9.10. Japan Vaccines Market Outlook
9.10.1. Market Size By Value
9.10.2. Market Size and Forecast By Technology
9.10.3. Market Size and Forecast By End-User
9.10.4. Market Size and Forecast By Distribution Channel
9.11. India Vaccines Market Outlook
9.11.1. Market Size By Value
9.11.2. Market Size and Forecast By Technology
9.11.3. Market Size and Forecast By End-User
9.11.4. Market Size and Forecast By Distribution Channel
9.12. Australia Vaccines Market Outlook
9.12.1. Market Size By Value
9.12.2. Market Size and Forecast By Technology
9.12.3. Market Size and Forecast By End-User
9.12.4. Market Size and Forecast By Distribution Channel
9.13. South Korea Vaccines Market Outlook
9.13.1. Market Size By Value
9.13.2. Market Size and Forecast By Technology
9.13.3. Market Size and Forecast By End-User
9.13.4. Market Size and Forecast By Distribution Channel
10. South America Vaccines Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Technology
10.4. Market Size and Forecast, By End-User
10.5. Market Size and Forecast, By Distribution Channel
10.6. Market Size and Forecast, By Type
10.7. Market Size and Forecast, By Route of Administration
10.8. Market Size and Forecast, By Disease
10.9. Brazil Vaccines Market Outlook
10.9.1. Market Size By Value
10.9.2. Market Size and Forecast By Technology
10.9.3. Market Size and Forecast By End-User
10.9.4. Market Size and Forecast By Distribution Channel
10.10. Argentina Vaccines Market Outlook
10.10.1. Market Size By Value
10.10.2. Market Size and Forecast By Technology
10.10.3. Market Size and Forecast By End-User
10.10.4. Market Size and Forecast By Distribution Channel
10.11. Columbia Vaccines Market Outlook
10.11.1. Market Size By Value
10.11.2. Market Size and Forecast By Technology
10.11.3. Market Size and Forecast By End-User
10.11.4. Market Size and Forecast By Distribution Channel
11. Middle East & Africa Vaccines Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Technology
11.4. Market Size and Forecast, By End-User
11.5. Market Size and Forecast, By Distribution Channel
11.6. Market Size and Forecast, By Type
11.7. Market Size and Forecast, By Route of Administration
11.8. Market Size and Forecast, By Disease
11.9. UAE Vaccines Market Outlook
11.9.1. Market Size By Value
11.9.2. Market Size and Forecast By Technology
11.9.3. Market Size and Forecast By End-User
11.9.4. Market Size and Forecast By Distribution Channel
11.10. Saudi Arabia Vaccines Market Outlook
11.10.1. Market Size By Value
11.10.2. Market Size and Forecast By Technology
11.10.3. Market Size and Forecast By End-User
11.10.4. Market Size and Forecast By Distribution Channel
11.11. South Africa Vaccines Market Outlook
11.11.1. Market Size By Value
11.11.2. Market Size and Forecast By Technology
11.11.3. Market Size and Forecast By End-User
11.11.4. Market Size and Forecast By Distribution Channel
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2022
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Merck & Co., Inc
12.6.2. BioNTech SE
12.6.3. Bavarian Nordic
12.6.4. GlaxoSmithKline PLC
12.6.5. Bharat Biotech International Limited
12.6.6. CSL
12.6.7. Charles River Laboratories
12.6.8. Creative Biogene
12.6.9. Daiichi Sankto Company Ltd
12.6.10. Emergent BioSolutions Inc.
12.6.11. Sanofi S.A
12.6.12. Serum Institute of India Pvt. Ltd
12.6.13. Sinovac
12.6.14. AstraZeneca plc
12.6.15. Novavax
12.6.16. Oxford Biomedica
12.6.17. Pfizer Inc
12.6.18. Takeda Pharmaceutical Company Limited
12.6.19. Inovio Pharmaceutical
12.6.20. Walvax Biotechnology Co., Ltd.
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
14.3. Related Reports
15. Disclaimer

List of Figures
Figure 1: Global Vaccines Market Size (USD Billion) By Region, 2022 & 2028
Figure 2: Market attractiveness Index, By Region 2028
Figure 3: Market attractiveness Index, By Segment 2028
Figure 4: Global Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 5: Global Vaccines Market Share By Region (2022)
Figure 6: North America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 7: North America Vaccines Market Share By Country (2022)
Figure 8: US Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 9: Canada Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 10: Mexico Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 11: Europe Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 12: Europe Vaccines Market Share By Country (2022)
Figure 13: Germany Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 14: UK Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 15: France Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 16: Italy Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 17: Spain Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 18: Russia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 19: Asia-Pacific Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 20: Asia-Pacific Vaccines Market Share By Country (2022)
Figure 21: China Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 22: Japan Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 23: India Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 24: Australia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 25: South Korea Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 26: South America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 27: South America Vaccines Market Share By Country (2022)
Figure 28: Brazil Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 29: Argentina Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 30: Columbia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 31: Middle East & Africa Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 32: Middle East & Africa Vaccines Market Share By Country (2022)
Figure 33: UAE Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 34: Saudi Arabia Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 35: South Africa Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 36: Competitive Dashboard of top 5 players, 2022
Figure 37: Market Share insights of key players, 2022
Figure 38: Porter's Five Forces of Global Vaccines Market

List of Table
Table 1 : Global Vaccines Market Snapshot, By Segmentation (2022 & 2028) (in USD Billion)
Table 2 : Influencing Factors for Vaccines Market, 2022
Table 3: Top 10 Counties Economic Snapshot 2020
Table 4: Economic Snapshot of Other Prominent Countries 2020
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Vaccines Market Size and Forecast, By Geography (2017 to 2028F) (In USD Billion)
Table 7 : Global Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 8 : Global Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 9 : Global Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 10 : Global Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 11 : Global Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 12 : Global Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 13 : North America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 14 : North America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 15 : North America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 16 : North America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 17 : North America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 18 : North America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 19 : United States Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 20 : United States Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 21 : United States Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 22 : Canada Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 23 : Canada Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 24 : Canada Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 25 : Mexico Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 26 : Mexico Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 27 : Mexico Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 28 : Europe Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 29 : Europe Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 30 : Europe Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 31 : Europe Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 32 : Europe Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 33 : Europe Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 34 : Germany Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 35 : Germany Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 36 : Germany Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 37 : United Kingdom Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 38 : United Kingdom Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 39 : United Kingdom Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 40 : France Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 41 : France Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 42 : France Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 43 : Italy Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 44 : Italy Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 45 : Italy Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 46 : Spain Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 47 : Spain Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 48 : Spain Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 49 : Russia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 50 : Russia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 51 : Russia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 52 : Asia-Pacific Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 53 : Asia-Pacific Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 54 : Asia-Pacific Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 55 : Asia-Pacific Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 56 : Asia-Pacific Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 57 : Asia Pacific Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 58 : China Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 59 : China Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 60 : China Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 61 : Japan Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 62 : Japan Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 63 : Japan Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 64 : India Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 65 : India Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 66 : India Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 67 : Australia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 68 : Australia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 69 : Australia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 70 : South Korea Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 71 : South Korea Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 72 : South Korea Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 73 : South America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 74 : South America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 75 : South America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 76 : South America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 77 : South America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 78 : South America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 79 : Brazil Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 80 : Brazil Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 81 : Brazil Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 82 : Argentina Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 83 : Argentina Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 84 : Argentina Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 85 : Colombia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 86 : Colombia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 87 : Colombia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 88 : Middle East & Africa Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 89 : Middle East & Africa Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 90 : Middle East & Africa Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 91 : Middle East & Africa Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 92 : Middle East & Africa Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 93 : Middle East & Africa Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 94 : United Arab Emirates Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 95 : United Arab Emirates Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 96 : United Arab Emirates Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 97 : Saudi Arabia Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 98 : Saudi Arabia Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 99 : Saudi Arabia Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 100 : South Africa Vaccines Market Size and Forecast By Technology (2017 to 2028F) (In USD Billion)
Table 101 : South Africa Vaccines Market Size and Forecast By End-User (2017 to 2028F) (In USD Billion)
Table 102 : South Africa Vaccines Market Size and Forecast By Distribution Channel (2017 to 2028F) (In USD Billion)

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（環境・エネルギー）の最新刊レポート

Bonafide Research & Marketing Pvt. Ltd.社のLifescience 分野での最新刊レポート

本レポートと同じKEY WORD（vaccines）の最新刊レポート


よくあるご質問


Bonafide Research & Marketing Pvt. Ltd.社はどのような調査会社ですか?


Bonafide Research & Marketing Pvt. Ltd.は、最新の経済、人口統計、貿易、市場データを提供する市場調査・コンサルティング会社です。調査レポート、カスタムレポート、コ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/19　10:26

155.48 円

165.11 円

199.74 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.